The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept
Abstract
Purpose: The Vδ1+ subset of γδ T lymphocytes is a promising candidate for cancer immunotherapy, but the lack of suitable expansion/differentiation methods has precluded therapeutic application. We set out to develop and test (preclinically) a Vδ1+ T-cell–based protocol that is good manufacturing practice compatible and devoid of feeder cells for prompt clinical translation. Experimental design: We tested multiple combinations of clinical-grade agonist antibodies and cytokines for their capacity to expand and differentiate (more than 2–3 weeks) Vδ1+ T cells from the peripheral blood of healthy donors and patients with chronic lymphocytic leukemia (CLL). We characterized the phenotype and functional potential of the final cellular product, termed Delta One T (DOT) cells, in vitro and in vivo (xenograft models of CLL). Results: We describe a very robust two-step protocol for the selective expansion (up to 2,000-fold in large clinical-grade cell culture bags) and differentiation of cytotoxic Vδ1+ (DOT) cells. These expressed the natural cytotoxicity receptors, NKp30 and NKp44, which synergized with the T-cell receptor to mediate leukemia cell targeting in vitro. When transferred in vivo, DOT cells infiltrated tumors and peripheral organs, and persisted until the end of the analysis without showing signs of loss of function; indeed, DOT cells proliferated and produced abundant IFNγ and TNFα, but importantly no IL17, in vivo. Critically, DOT cells were capable of inhibiting tumor growth and preventing dissemination in xenograft models of CLL. Conclusions: We provide a clinical-grade method and the preclinical proof of principle for application of a new cellular product, DOT cells, in adoptive immunotherapy of CLL. Clin Cancer Res; 22(23); 5795–804. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Bonneville, M., O'Brien, R. L., & Born, W. K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2781 · Cited by 952
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Silva-Santos, B., Serre, K., & Norell, H. (2015) · Nature reviews. Immunology · doi:10.1038/nri3904 · Cited by 565
Self-citationFive Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
Ribeiro, S. T., Ribot, J. C., & Silva-Santos, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00015 · Cited by 116 · cited 1×
“In contrast, key inhibitory and exhaustion-associated molecules such as PD-1, CTLA-4, or CD94 (24) were expressed either at very low levels or not expressed at all (Fig.”
BackgroundSelf-citation
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Self-citationGuidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Silva-Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 425
Self-citationTranslating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., & Kuball, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0038-z · Cited by 425
Self-citationγδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Metadata
- Authors
- Almeida, A. R., Correia, D. V., Fernandes-Platzgummer, A., da Silva, C. L., da Silva, M. G., Anjos, D. R., & Silva-Santos, B.
- Venue
- Clinical Cancer Research
- Published
- 2016-11-30
- Volume
- 22
- Issue
- 23
- Pages
- 5795-5804
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2421681513
- Cited by
- 229
- References
- 6
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0597
- The paper
- Almeida, A. R., Correia, D. V., Fernandes-Platzgummer, A., da Silva, C. L., da Silva, M. G., Anjos, D. R., & Silva-Santos, B. (2016). Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0597
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.